Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A novel rigidizing overtube (ROT) was developed to facilitate endoscopic removal of complex gastrointestinal polyps. We aimed to prospectively evaluate the efficacy and safety of the device in the management of large gastrointestinal polyps.
Methods: A prospective, single-center study, conducted between May 2021 and April 2023, enrolled patients undergoing endoscopic resection of colon/duodenal polyps ≥25 mm. Primary outcomes were safety, technical success, and clinical success defined as the ability of ROT to facilitate endoscopic polyp removal without changing the initial resection method.
Results: 97 patients (98 polyps), with a mean polyp size of 33.2 mm (median 31.1), were evaluated. Technical and clinical success rates were 100% and 84%, respectively. Ileocecal valve location was the only predictor of clinical failure (P = 0.02). The mean time to reach the lesion was 7.2 minutes (95%CI 5-8), with overall resection and procedure times of 53.6 minutes (95%CI 48-61) and 88.9 minutes (95%CI 79-95), respectively. No device-related adverse events occurred. Lower technical (67%) and clinical (67%) success rates were seen for duodenal polyps (n = 6).
Conclusion: The novel ROT was safe, with high technical and clinical success during resection of complex colon polyps. Future studies will determine timing of implementation during routine endoscopic resection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2350-4059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left Bundle Branch-Optimized Cardiac Resynchronization Therapy in a Patient with a Carillon Annuloplasty Device: Challenges and Solutions-Uncorrected Proof.
Turk Kardiyol Dern Ars
September 2025
Department of Cardiology, Necmettin Erbakan University, School of Medicine, Konya, Turkiye.
Cardiac resynchronization therapy (CRT) improves outcomes in heart failure, but prior interventions like percutaneous mitral annuloplasty may hinder lead placement. We present a 70-year-old male with ischemic cardiomyopathy and severe functional mitral regurgitation who previously received a Carillon device. Due to coronary sinus inaccessibility, left bundle branch area pacing optimized cardiac resynchronization therapy (LOT-CRT) was performed.
View Article and Find Full Text PDFJanus Kinase Inhibitors as A Breakthrough Treatment for Refractory Dissecting Cellulitis of the Scalp.
Eur J Case Rep Intern Med
August 2025
Dermatology Department, Ain Shams University Hospital, Cairo, Egypt.
Background: Dissecting cellulitis of the scalp (DCS) is a rare, chronic neutrophilic dermatosis that is often refractory to conventional therapies.
Case Report: We present a 29-year-old male with treatment-resistant DCS who achieved rapid and sustained remission following off-label use of tofacitinib, a Janus kinase (JAK) inhibitor. Previous therapies, including antibiotics, corticosteroids, and isotretinoin, had failed.
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.
Front Immunol
September 2025
Department of Pathological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States.
Oncolytic virotherapy (OVT) has emerged as a promising and innovative cancer treatment strategy that harnesses engineered viruses to selectively infect, replicate within, and destroys malignant cells while sparing healthy tissues. Beyond direct oncolysis, oncolytic viruses (OVs) exploit tumor-specific metabolic, antiviral, and immunological vulnerabilities to reshape the tumor microenvironment (TME) and initiate systemic antitumor immunity. Despite promising results from preclinical and clinical studies, several barriers, including inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, continue to limit the therapeutic advantages of OVT as a standalone modality and hindered its clinical success.
View Article and Find Full Text PDFNutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?
Front Immunol
September 2025
Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
In the last decades, immunotherapy has revolutionized cancer treatment. Despite its success, a significant number of patients fail to respond, and the underlying causes of ineffectiveness remain poorly understood. Factors such as nutritional status and body composition are emerging as key predictors of immunotherapy outcomes.
View Article and Find Full Text PDFImpact of vascular risk factors on endovascular mechanical thrombectomy outcomes in patients with stroke.
Biomed Rep
November 2025
Neurology Department, Neuroscience Center, King Fahad Specialist Hospital-Dammam, Dammam 32253-3202, Saudi Arabia.
Endovascular mechanical thrombectomy (MT) is a recommended treatment for acute ischemic stroke due to large vessel occlusion (LVO). The objective of the present study was to evaluate the impact of vascular risk factors on the outcome of MT outcomes in patients with stroke with LVO and to determine the prevalence of structural epilepsy in these patients. This was a retrospective cohort study involving patients with stroke between 20 and 80 years of age with LVO who underwent MT.
View Article and Find Full Text PDF